Last reviewed · How we verify
PEG-IFN alfa-2b
PEG-IFN alfa-2b is a Small molecule drug developed by Merck Sharp & Dohme LLC. It is currently FDA-approved. Also known as: SCH 054031, PegIntron, PegIntron™.
At a glance
| Generic name | PEG-IFN alfa-2b |
|---|---|
| Also known as | SCH 054031, PegIntron, PegIntron™ |
| Sponsor | Merck Sharp & Dohme LLC |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia (PHASE2)
- Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma (PHASE2)
- A Clinical Study of Gecacitinib Combined With Pegylated Interferon in Patients With PV (NA)
- Safety, Tolerability, and Preliminary Efficacy of Peginterferon α-2b in Combination With an Anti-PD-1 Antibody in Patients With Advanced or Metastatic Malignant Solid Tumors (NA)
- Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer (PHASE1)
- Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Relapser Genotype 2 Hepatitis C Infected Patients (PHASE3)
- A Phase 1 Study of MP-424, Peginterferon Alfa 2b, and Ribavirin in Hepatitis C (PHASE1)
- Efficacy and Safety of MP-424, Peginterferon Alfa-2b, and Ribavirin in Patients With Chronic Hepatitis C Who Relapsed After Previous Interferon Based Therapy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PEG-IFN alfa-2b CI brief — competitive landscape report
- PEG-IFN alfa-2b updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI
Frequently asked questions about PEG-IFN alfa-2b
What is PEG-IFN alfa-2b?
PEG-IFN alfa-2b is a Small molecule drug developed by Merck Sharp & Dohme LLC.
Who makes PEG-IFN alfa-2b?
PEG-IFN alfa-2b is developed and marketed by Merck Sharp & Dohme LLC (see full Merck Sharp & Dohme LLC pipeline at /company/merck).
Is PEG-IFN alfa-2b also known as anything else?
PEG-IFN alfa-2b is also known as SCH 054031, PegIntron, PegIntron™.
What development phase is PEG-IFN alfa-2b in?
PEG-IFN alfa-2b is FDA-approved (marketed).
Related
- Manufacturer: Merck Sharp & Dohme LLC — full pipeline
- Also known as: SCH 054031, PegIntron, PegIntron™
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing